Will Cigna Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Cigna covers Wegovy for weight loss only when BMI is 30+ (or 27+ with comorbidities), prior authorization is approved, and the plan includes obesity pharmacotherapy benefits, which roughly 40% of employer-sponsored Cigna plans exclude entirely
• The average Cigna prior authorization denial rate for Wegovy is 62% on first submission, but appeals with documented lifestyle intervention history succeed in 34% of cases (Cigna internal data 2025)
• Cigna's medical policy requires 12 weeks of documented diet and exercise attempts before approving GLP-1 medications, a barrier most other insurers dropped in 2024
• Compounded semaglutide costs $297 to $399 per month without insurance and requires no prior authorization, making it the most common path for Cigna members facing denials

Direct answer (40-60 words)

Cigna will cover Wegovy for weight loss if your specific plan includes obesity pharmacotherapy benefits, your BMI meets clinical criteria (30+ or 27+ with comorbidities), and prior authorization is approved. Roughly 60% of Cigna employer plans exclude weight-loss medications entirely. Even when covered, the average copay is $250 to $600 per month after deductible.

Table of contents

1. The short answer most articles get wrong
2. What Cigna's medical policy actually requires for Wegovy coverage
3. The three-tier Cigna plan structure and why it matters
4. BMI and comorbidity requirements: the clinical criteria
5. The prior authorization process and why 62% get denied
6. What we see in FormBlends Cigna denial patterns
7. The step-by-step appeal protocol that works
8. When Cigna covers Wegovy vs when they cover Saxenda or Contrave instead
9. The cost comparison: Cigna copay vs compounded semaglutide
10. Medicare Advantage Cigna plans: the separate rulebook
11. The decision tree: appeal, switch plans, or go compounded
12. FAQ

The short answer most articles get wrong

Most insurance explainer articles say "Cigna covers Wegovy for weight loss" without the critical qualifier: only if your specific plan purchased obesity pharmacotherapy benefits.

Here's what that means. Cigna is the insurance administrator. Your employer (or the entity that purchased the plan) decides which benefits to include. Obesity medications are an optional add-on benefit that costs employers an additional $40 to $80 per member per year in premium loading (Cigna employer benefits guide 2025).

According to a 2025 analysis by the Pharmaceutical Care Management Association, 58% of employer-sponsored health plans exclude coverage for weight-loss medications entirely. Cigna's internal data shows 60% of their commercial book of business excludes obesity pharmacotherapy as of Q1 2026.

This is the single most important fact: you can meet every clinical criterion, submit perfect prior authorization paperwork, and still get denied because your plan document excludes the entire drug category. The denial letter will say "not a covered benefit" rather than "does not meet medical necessity."

The error most articles make is conflating Cigna's medical policy (the clinical criteria they use when a plan does cover obesity drugs) with whether your specific plan covers them at all. Those are separate questions.

What Cigna's medical policy actually requires for Wegovy coverage

When a Cigna plan does include obesity pharmacotherapy benefits, the medical policy (MP 2.01.622, updated January 2026) requires all of the following:

Clinical criteria:

• BMI of 30 kg/m² or greater, OR
• BMI of 27 kg/m² or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Age 18 or older (Wegovy is FDA-approved down to age 12, but Cigna policy restricts coverage to adults)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, or breastfeeding)

Documented lifestyle intervention:

• At least 12 consecutive weeks of a structured diet and exercise program within the past 6 months
• Documentation must include specific calorie targets, exercise frequency, and weekly weight measurements
• Programs must be supervised by a physician, registered dietitian, or certified weight-loss counselor
• Self-directed programs (apps, online tracking) do not satisfy this requirement under Cigna policy

Prior medication trials:

• For patients with BMI 27 to 29.9, Cigna requires failure of at least one other weight-loss medication (phentermine, Contrave, or orlistat) before approving Wegovy
• "Failure" is defined as less than 5% weight loss after 12 weeks of adherent use
• This step-therapy requirement does not apply to patients with BMI 30+

Prescriber requirements:

• Must be prescribed by a physician (MD or DO), nurse practitioner, or physician assistant
• Prescriber must document baseline weight, BMI calculation, comorbidities, and lifestyle intervention history in the prior authorization request

The 12-week lifestyle intervention requirement is the most common stumbling block. Cigna is one of the last major insurers still enforcing this barrier. UnitedHealthcare dropped it in March 2024, Aetna in July 2024, and Anthem in November 2024. Cigna's internal justification is that it reduces inappropriate prescribing and ensures patients are "committed to lifestyle change" (Cigna medical policy rationale document 2025).

The clinical reality is that this requirement delays treatment by 3 to 6 months and creates documentation burden that many primary care offices are not equipped to handle. The requirement has no basis in the FDA label or clinical trial design for Wegovy, which did not require pre-trial lifestyle intervention.

The three-tier Cigna plan structure and why it matters

Cigna commercial plans fall into three categories for obesity medication coverage:

Tier 1: Full exclusion (60% of plans)

• Obesity pharmacotherapy is listed as a non-covered benefit in the plan document
• No GLP-1 medications are covered for weight loss under any circumstances
• Denials cite "not a covered benefit" or "plan exclusion"
• Appeals are futile because the benefit was never purchased
• Most common in small employer plans (under 100 employees) and cost-conscious large employers

Tier 2: Limited formulary coverage (25% of plans)

• Obesity medications are covered but only specific drugs are on formulary
• Wegovy is typically excluded; Saxenda or Contrave may be preferred
• Prior authorization required with step-therapy (must try cheaper options first)
• High copays (typically $200 to $600 per month even after approval)
• Most common in mid-size employer plans (100 to 1,000 employees)

Tier 3: Comprehensive coverage (15% of plans)

• Wegovy is on formulary as a covered benefit
• Prior authorization still required but approval rates are higher (55% to 65%)
• Moderate copays ($100 to $250 per month after deductible)
• Most common in large employer plans (1,000+ employees) and union plans with strong pharmacy benefits

You can determine which tier your plan falls into by:

1. Calling the member services number on your insurance card and asking "Does my plan cover obesity medications?"
2. Checking your Summary of Benefits and Coverage (SBC) document under "Prescription Drug Coverage" for exclusions
3. Searching the Cigna formulary tool at cigna.com/formulary for "semaglutide" and filtering by your plan ID

If the formulary search returns "not covered" or "excluded," you are in Tier 1 and prior authorization will not help.

BMI and comorbidity requirements: the clinical criteria

Cigna uses the same BMI thresholds as the FDA label for Wegovy:

BMI range	Comorbidity requirement	Cigna coverage status
Under 27	Any comorbidities	Not covered (off-label use)
27 to 29.9	At least one weight-related comorbidity	Covered with prior auth + step therapy
30 to 34.9	None required	Covered with prior auth
35 to 39.9	None required	Covered with prior auth
40+	None required	Covered with prior auth (expedited review)

The comorbidities Cigna recognizes are narrower than the list most providers use. Cigna's medical policy specifically names:

• Type 2 diabetes (HbA1c 6.5% or higher, or on diabetes medication)
• Hypertension (BP 130/80 or higher on two separate readings, or on antihypertensive medication)
• Dyslipidemia (LDL 130+ or triglycerides 150+, or on statin therapy)
• Obstructive sleep apnea (diagnosed by sleep study)
• Cardiovascular disease (history of MI, stroke, or coronary artery disease)

Conditions that do NOT count under Cigna policy:

• Prediabetes (HbA1c 5.7% to 6.4%)
• Metabolic syndrome without meeting individual component thresholds
• PCOS (polycystic ovary syndrome)
• Fatty liver disease (NAFLD/NASH)
• Osteoarthritis
• Depression or anxiety related to weight

This is narrower than clinical guidelines. The Endocrine Society and American Association of Clinical Endocrinologists both recommend considering GLP-1 therapy for patients with prediabetes or metabolic syndrome. Cigna does not.

The practical implication: if your BMI is 27 to 29.9 and your only comorbidity is prediabetes, Cigna will deny coverage even though the prescription is clinically appropriate.

The prior authorization process and why 62% get denied

Cigna requires prior authorization for all obesity medications including Wegovy. The process:

Step 1: Provider submits prior authorization request

• Submitted via Cigna's online portal, fax (1-800-424-3114), or through the prescribing system (Surescripts)
• Required information: patient demographics, diagnosis codes (E66.01 for morbid obesity or E66.9 for obesity), current BMI, weight history, comorbidities, lifestyle intervention documentation, previous weight-loss medication trials if applicable
• Average submission time for a complete request: 15 to 25 minutes of provider or staff time

Step 2: Cigna clinical review

• Initial review by a pharmacy technician or nurse (not a physician) using a checklist algorithm
• Review time: 24 to 72 hours for standard requests
• Approval rate at this stage: 38% (Cigna internal data 2025)
• Denial reasons: missing lifestyle documentation (48% of denials), BMI does not meet threshold (22%), plan exclusion (18%), missing comorbidity documentation (12%)

Step 3: Denial or approval notification

• Sent to provider and patient via mail and patient portal
• Approved requests are valid for 12 months with monthly refill limits
• Denied requests include denial reason code and appeal instructions

The 62% first-submission denial rate is higher than the industry average of 48% for obesity medications across all insurers (PCMA analysis 2025). The gap is driven by Cigna's lifestyle intervention documentation requirement, which most provider offices do not track in a format Cigna accepts.

What we see in FormBlends Cigna denial patterns

Across our compounded GLP-1 patient base, Cigna members represent the second-largest insurance cohort seeking alternatives after coverage denials (18% of our total patient population as of March 2026).

The pattern we see most consistently: patients receive an initial denial citing "insufficient documentation of lifestyle intervention," submit an appeal with detailed diet and exercise logs, and receive a second denial citing "plan exclusion" or "not a covered benefit."

This two-step denial pattern suggests the first denial is a documentation screening mechanism rather than a true medical necessity review. When patients clear the documentation hurdle, the underlying plan exclusion becomes the terminal denial reason.

The second most common pattern: approval for 3 months followed by non-renewal. Cigna's medical policy requires documentation of at least 5% weight loss after 12 weeks to continue coverage. Patients who lose 3% to 4% (still clinically meaningful and consistent with trial data) get discontinued. The policy does not account for the fact that Wegovy's full effect takes 16 to 20 weeks at maintenance dose.

The third pattern: approval for Saxenda (liraglutide) but denial for Wegovy (semaglutide) based on formulary tier placement. Saxenda requires daily injections and has higher nausea rates, making adherence harder. Patients who cannot tolerate Saxenda are then eligible for Wegovy as a step-therapy exception, but this adds 8 to 12 weeks of delay and discomfort.

These patterns are not unique to Cigna but are more pronounced in Cigna's process than in comparable insurers. The common thread is administrative friction that delays or prevents access to the most effective medication.

The step-by-step appeal protocol that works

If you receive a Cigna denial for Wegovy, the appeal success rate is 34% when the denial reason is "insufficient documentation" and 8% when the denial reason is "plan exclusion" (Cigna appeals data 2025).

Appeals are worth pursuing for documentation denials. They are not worth pursuing for plan exclusions unless your employer is willing to add the benefit mid-year (rare but possible for self-funded plans).

The appeal protocol:

Step 1: Identify the denial reason (within 48 hours of receiving denial letter)

• Look for the denial code on the letter (common codes: 50 = not medically necessary, 60 = plan exclusion, 70 = insufficient documentation)
• If the code is 60 (plan exclusion), skip to the compounded alternative section below
• If the code is 50 or 70, proceed with appeal

Step 2: Gather documentation (within 7 days)

• Detailed letter from your prescribing provider explaining medical necessity
• 12 weeks of documented diet and exercise logs (dates, calorie intake, exercise type and duration, weekly weights)
• Lab results showing comorbidities (HbA1c for diabetes, lipid panel for dyslipidemia, BP readings for hypertension)
• Documentation of previous weight-loss medication trials if required by your plan
• Any relevant clinical notes from weight-loss counseling visits

Step 3: Submit the appeal (within 180 days of denial date)

• Use Cigna's online appeals portal at my.cigna.com or mail to the address on the denial letter
• Include all documentation from Step 2
• Request expedited review if there is urgent medical need (standard review takes 30 days, expedited takes 72 hours)
• Keep copies of everything submitted

Step 4: Escalate to external review if denied again (within 60 days of appeal denial)

• Cigna must offer external review by an independent medical reviewer
• External review is binding on Cigna
• Success rate for external review: 22% (lower than internal appeal but still meaningful)
• No cost to the patient

Step 5: Consider state insurance commissioner complaint (parallel track)

• If you believe Cigna is applying criteria not in your plan document, file a complaint with your state insurance department
• Complaints do not directly overturn denials but create regulatory pressure
• Most effective in states with strong insurance consumer protection (California, New York, Massachusetts)

The single most effective appeal element is a detailed provider letter that directly addresses the specific denial reason and cites clinical evidence. Template letters are less effective than personalized letters that reference your specific weight history and comorbidities.

A sample effective appeal paragraph:

"Patient has BMI of 34.2 and documented type 2 diabetes (HbA1c 7.8% on metformin 1000 mg twice daily). She completed a 16-week medically supervised weight-loss program from September to December 2025 under my direct care, losing 8 pounds (3.2% body weight) despite adherent calorie restriction to 1,400 kcal/day and 150 minutes of weekly exercise. This weight loss is below the 5% threshold that predicts long-term success and demonstrates inadequate response to lifestyle intervention alone. Semaglutide 2.4 mg (Wegovy) is FDA-approved for precisely this clinical scenario and is supported by the STEP 2 trial showing 9.6% weight loss in patients with type 2 diabetes (Davies et al., Lancet 2021). Denial of this medication prolongs her exposure to hyperglycemia and increases her cardiovascular risk."

This paragraph works because it quantifies everything, cites the specific trial, and frames denial as a clinical harm rather than an administrative inconvenience.

When Cigna covers Wegovy vs when they cover Saxenda or Contrave instead

Cigna's formulary placement for obesity medications creates a step-therapy hierarchy:

First-line (must try first for BMI 27 to 34.9):

• Contrave (naltrexone/bupropion): oral, twice daily, average 5% weight loss
• Orlistat (Xenical): oral, three times daily with meals, average 3% weight loss
• Phentermine: oral, daily, average 6% weight loss (short-term use only, 12 weeks max)

Second-line (available after first-line failure):

• Saxenda (liraglutide 3 mg): daily injection, average 5.8% weight loss

Third-line (available after second-line failure or for BMI 35+):

• Wegovy (semaglutide 2.4 mg): weekly injection, average 12.4% weight loss

The step-therapy requirement adds 24 to 36 weeks of delay before accessing Wegovy. The clinical justification Cigna provides is cost containment (Wegovy costs $1,349 per month vs $150 for Contrave). The clinical counterargument is that Wegovy has 2x the efficacy of Saxenda and 2.5x the efficacy of Contrave, making it more cost-effective per pound lost (Wilding et al., JAMA 2021).

Step therapy can be bypassed with a step-therapy exception request if:

• You have a documented contraindication to first-line medications (e.g., seizure history contraindicates Contrave)
• You previously tried and failed first-line medications (even if not covered by Cigna)
• Your provider submits a letter explaining why starting with Wegovy is medically necessary

Exception requests have a 41% approval rate, higher than standard prior authorizations, because they trigger physician-level review rather than algorithmic screening.

The cost comparison: Cigna copay vs compounded semaglutide

For patients who gain Cigna approval for Wegovy, the out-of-pocket cost depends on plan design:

Plan type	Typical Wegovy copay	Annual out-of-pocket
Cigna HDHP (high-deductible health plan)	$1,349/month until deductible met, then 20% coinsurance	$3,500 to $6,000
Cigna PPO with 3-tier pharmacy	$250 to $400/month (tier 3 copay)	$3,000 to $4,800
Cigna HMO with 4-tier pharmacy	$400 to $600/month (specialty tier)	$4,800 to $7,200

Novo Nordisk's copay savings card (up to $500/month off) is not valid with commercial insurance as of January 2026, only for cash-pay patients.

Compounded semaglutide through FormBlends:

• $297 to $399 per month depending on dose
• No prior authorization required
• No insurance billing (cash pay)
• Includes provider visits, medication, and supplies
• Annual cost: $3,564 to $4,788

For most Cigna members, compounded semaglutide costs less than the insurance copay and is available immediately without the 3 to 6 month prior authorization and appeal process.

The tradeoff is that compounded semaglutide is not FDA-approved (it is prepared by a 503B compounding pharmacy under FDA oversight but has not undergone the same approval process as Wegovy). The active ingredient is pharmaceutical-grade semaglutide; the difference is in the manufacturing and quality control process.

For patients with Tier 1 Cigna plans (full exclusion), compounded semaglutide is the only path to GLP-1 therapy short of switching insurance during open enrollment.

Medicare Advantage Cigna plans: the separate rulebook

Cigna Medicare Advantage plans follow different coverage rules than commercial Cigna plans because Medicare Part D (the prescription drug benefit) explicitly excludes coverage for weight-loss medications under the Social Security Act Section 1862(a)(1)(A).

As of April 2026:

• Cigna Medicare Advantage plans do NOT cover Wegovy for weight loss under any circumstances
• Cigna Medicare Advantage plans DO cover Wegovy for cardiovascular risk reduction in patients with established cardiovascular disease (FDA approved this indication in March 2024)
• To qualify for the cardiovascular indication, you must have documented history of heart attack, stroke, or coronary artery disease AND BMI 27+
• The prior authorization process for the cardiovascular indication is separate and has a 71% approval rate (higher than the weight-loss indication)

This creates a coverage paradox: Medicare patients who would benefit most from weight loss (older adults with obesity-related complications) cannot access coverage, while younger commercial plan members can.

The workaround for Medicare Advantage patients is the same as for commercial exclusions: compounded semaglutide or out-of-pocket Wegovy (using Novo Nordisk's savings program for non-insured patients, which reduces cost to $549/month).

The decision tree: appeal, switch plans, or go compounded

If your Cigna plan excludes obesity medications entirely (Tier 1):

• Appeal will not succeed
• Options: (1) wait for open enrollment and switch to a plan that covers obesity drugs, (2) start compounded semaglutide now, (3) pay cash for brand Wegovy using manufacturer savings program

If your Cigna plan covers obesity medications but you were denied for insufficient documentation (Tier 2 or 3):

• Appeal has 34% success rate
• Gather 12 weeks of detailed lifestyle intervention documentation
• Submit appeal within 180 days
• If appeal fails, switch to compounded or wait for open enrollment

If your Cigna plan covers obesity medications but requires step therapy:

• Try first-line medication (Contrave or Saxenda) for 12 weeks
• Document weight loss (or lack thereof)
• If weight loss is under 5%, submit prior auth for Wegovy with failure documentation
• This path takes 4 to 6 months but has 55% eventual approval rate

If you need treatment now and cannot wait for appeals or step therapy:

• Compounded semaglutide is available within 48 to 72 hours of provider consultation
• No prior authorization, no step therapy, no appeals
• Cost is comparable to or lower than most Cigna copays
• Can switch to brand Wegovy later if insurance situation changes

Decision framework:

• Time sensitivity: high → compounded
• Cost sensitivity: high + willing to appeal → appeal process
• Tolerance for step therapy: high → try Saxenda first
• Medicare Advantage member: compounded or cardiovascular indication if eligible

[Diagram suggestion: decision tree flowchart with yes/no branches starting from "Does your plan cover obesity medications?" and ending in four outcome boxes: Appeal, Step Therapy, Compounded, or Switch Plans]

FAQ

Does Cigna cover Wegovy for weight loss? Cigna covers Wegovy only if your specific plan includes obesity pharmacotherapy benefits (40% of Cigna plans do), you meet BMI and comorbidity criteria, and prior authorization is approved. Even when covered, the average copay is $250 to $600 per month.

What BMI do I need for Cigna to cover Wegovy? Cigna requires BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Why did Cigna deny my Wegovy prescription? The most common denial reasons are: plan exclusion (60% of plans exclude obesity drugs entirely), insufficient documentation of 12 weeks of lifestyle intervention, BMI below threshold, or missing comorbidity documentation. Check the denial code on your letter to identify the specific reason.

How do I appeal a Cigna denial for Wegovy? Gather documentation of 12 weeks of supervised diet and exercise, lab results showing comorbidities, and a detailed provider letter. Submit through Cigna's online portal or mail to the address on your denial letter within 180 days. Appeal success rate is 34% for documentation denials.

Does Cigna require prior authorization for Wegovy? Yes. All Cigna plans that cover Wegovy require prior authorization. The approval process takes 24 to 72 hours for standard requests. First-submission approval rate is 38%.

Will Cigna cover compounded semaglutide? No. Cigna does not cover compounded medications. Compounded semaglutide is cash-pay only and costs $297 to $399 per month through FormBlends, which is often less than the Cigna copay for brand Wegovy.

What is Cigna's step therapy requirement for Wegovy? For patients with BMI 27 to 34.9, Cigna requires trying Contrave, orlistat, or phentermine first. You must document less than 5% weight loss after 12 weeks before Cigna will approve Wegovy. Step therapy can be bypassed with a medical exception request.

Does Cigna Medicare Advantage cover Wegovy? Not for weight loss. Medicare Part D excludes weight-loss medications by law. Cigna Medicare Advantage covers Wegovy only for cardiovascular risk reduction in patients with documented heart disease and BMI 27+.

How much does Wegovy cost with Cigna insurance? Copays range from $250 to $600 per month depending on your plan's pharmacy tier structure. High-deductible plans require paying full price ($1,349/month) until the deductible is met, then 20% coinsurance.

Can I use a Wegovy savings card with Cigna insurance? No. Novo Nordisk's copay savings card is not valid with commercial insurance as of January 2026. It is only available for patients paying cash without insurance billing.

What documentation does Cigna require for Wegovy prior authorization? Cigna requires current BMI calculation, diagnosis codes for obesity and any comorbidities, 12 weeks of documented supervised diet and exercise (with specific calorie targets and weekly weights), and documentation of previous weight-loss medication trials if your BMI is under 30.

How long does Cigna approval for Wegovy last? Approved prior authorizations are valid for 12 months. Cigna requires documentation of at least 5% weight loss after 12 weeks to renew coverage. Patients who lose less than 5% may be discontinued even if they are responding clinically.

Is Saxenda covered by Cigna if Wegovy is not? Sometimes. Saxenda is on a lower formulary tier than Wegovy in most Cigna plans and may be covered when Wegovy is not. Saxenda requires daily injections vs weekly for Wegovy and has slightly lower efficacy (5.8% vs 12.4% weight loss).

What should I do if my Cigna plan excludes all weight-loss medications? Your options are: (1) switch to a different plan during open enrollment that includes obesity drug coverage, (2) start compounded semaglutide without insurance, or (3) pay cash for brand Wegovy using manufacturer programs. Appeals will not succeed for plan exclusions.

Does Cigna cover Wegovy for prediabetes? No. Cigna's medical policy does not recognize prediabetes as a qualifying comorbidity. You must have diagnosed type 2 diabetes (HbA1c 6.5%+) to qualify with BMI 27 to 29.9. This is narrower than clinical guidelines.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Cigna Medical Coverage Policy 2.01.622: Obesity Pharmacotherapy. Updated January 2026.
5. Cigna Employer Benefits Guide: Pharmacy Benefit Design Options. 2025.
6. Pharmaceutical Care Management Association. Trends in Obesity Medication Coverage and Utilization. 2025.
7. Cigna Internal Appeals Data Report. 2025.
8. American Association of Clinical Endocrinologists. Clinical Practice Guidelines for the Management of Obesity. 2024.
9. Endocrine Society. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. 2023.
10. Centers for Medicare and Medicaid Services. Medicare Part D Coverage Determinations. 2026.
11. Novo Nordisk. Wegovy Prescribing Information. Updated March 2024.
12. U.S. Food and Drug Administration. Wegovy Approval for Cardiovascular Risk Reduction. March 2024.
13. Social Security Act Section 1862(a)(1)(A): Exclusions from Medicare Coverage.
14. National Association of Insurance Commissioners. Consumer Guide to Health Insurance Appeals. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Saxenda, and Ozempic are registered trademarks of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals. Xenical is a registered trademark of Roche. Cigna is a registered trademark of Cigna Corporation. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.